In a recent wave of scrutiny on private equity (PE) firms, the Federal Trade Commission (FTC) has launched a lawsuit against Welsh, Carson, Anderson & Stowe, a prominent PE firm, and U.S. Anesthesia Partners, Inc. (USAP), a key anesthesia service provider in Texas. The accusation revolves around the allegations that these organizations have inflated prices via a concerted anti-competitive plot to centralize Texas anesthesiology practices.
Historically, the FTC has maintained a keen interest in health care-related acquisitions. This comes as no surprise given the sector’s stature and influence over the economy. However, taking into account the FTC’s recent enforcement action, it seems apparent that the agency has notably shifted its focus towards PE transactional activity associated with doctor practice management companies and physician groups.
Details furnished by Venable LLP on the lawsuit suggest that the FTC is not merely limiting its oversight to potential horizontal competition issues, but is further engaging with vertical competition matters. This essentially means FTC is investigating both situations where the entities in question could be direct competitors (horizontal) and where they might occupy different stages of the same production process (vertical).
This novel approach introduces a more comprehensive oversight strategy, aimed at fully assessing the potential impact of such consolidations on competition across different stages of production and supply. Such stringent regulatory diligence could lead to increased complexities in the clearance of future M&A transactions for corporates and law firms.
In conclusion, this development not only signals a crucial shift in FTC’s enforcement strategy but also calls for companies and their legal counsels to consider potential competition issues at different stages of business operations. Corporates and law firms would be wise to reevaluate their business strategy, address such competition concerns, and carefully tailor their M&A transactions to avoid falling foul of this evolving regulatory landscape.